Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada

被引:38
作者
De Wals, P [1 ]
Petit, G
Erickson, LJ
Guay, M
Tam, T
Law, B
Framarin, A
机构
[1] Univ Laval, Dept Social & Prevent Med, Quebec City, PQ G1K 7P4, Canada
[2] Natl Publ Hlth Inst, Quebec City, PQ, Canada
[3] Sherbrooke Hosp Univ Ctr, Clin Res Ctr, Sherbrooke, PQ, Canada
[4] Univ Sherbrooke, Dept Community Hlth Sci, Sherbrooke, PQ J1K 2R1, Canada
[5] Reg Hlth Board Monteregie, Longueuil, PQ, Canada
[6] Hlth Canada, Ctr Infect Dis Prevent & Control, Ottawa, ON K1A 0L2, Canada
[7] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada
[8] Quebec Agcy Hlth Serv & Technol Assessment, Montreal, PQ, Canada
关键词
cost-effectiveness; pneumococcal vaccine; Canada;
D O I
10.1016/S0264-410X(03)00361-X
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To estimate cost-effectiveness of routine and catch-up vaccination of Canadian children with seven-valent pneumococcal Conjugate vaccine, a simulation model was constructed. In base scenario (vaccination coverage: 80%, and vaccine price: $58 per dose), pneumococcal disease incidence reduction would be superior to 60% for invasive infections, and to 30% for non-invasive infections, but the number of deaths prevented would be small. Annual costs of routine immunization would be $71 million (98% borne by the health system). Societal benefit to cost ratio would be 0.57. Net societal costs per averted pneumococcal disease would be $389 and 125,000 per life-year gained (LYG). Vaccine purchase cost is the most important variable in sensitivity analyses, and program costs would be Superior to societal benefits in all likely scenarios. Vaccination would result in net savings for society, if vaccine cost is less than $30 per dose. Economic indicators of catch-up programs are less favorable than for routine infant immunization. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:3757 / 3764
页数:8
相关论文
共 36 条
  • [21] Lovgren M, 1998, CAN MED ASSOC J, V158, P327
  • [22] Macdonald Noni, 2003, Can J Infect Dis, V14, P9
  • [23] THE CAUSES OF HOSPITAL-TREATED ACUTE LOWER RESPIRATORY-TRACT INFECTION IN CHILDREN
    NOHYNEK, H
    ESKOLA, J
    LAINE, E
    HALONEN, P
    RUUTU, P
    SAIKKU, P
    KLEEMOLA, M
    LEINONEN, M
    [J]. AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1991, 145 (06): : 618 - 622
  • [24] A benefit - cost analysis of two-dose measles immunization in Canada
    Pelletier, L
    Chung, P
    Duclos, P
    Manga, P
    Scott, J
    [J]. VACCINE, 1998, 16 (9-10) : 989 - 996
  • [25] PETER G, 1997, PRINCIPLES PRACTICE, P828
  • [26] PETIT G, IN PRESS CAN J INFEC
  • [27] RAMSEY BW, 1986, PEDIATRICS, V78, P1
  • [28] Invasive pneumococcal infections in Canadian children, 1991-1998: Implications for new vaccination strategies
    Scheifele, D
    Halperin, S
    Pelletier, L
    Talbot, J
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 31 (01) : 58 - 64
  • [29] Scheifele D W, 2000, Paediatr Child Health, V5, P371
  • [30] Prevention of pneumococcal disease by vaccination: does serotype replacement matter?
    Spratt, BG
    Greenwood, BM
    [J]. LANCET, 2000, 356 (9237) : 1210 - 1211